Reduced risk of dyslipidaemia with oolong tea consumption: a population-based study in southern China.
Experimental studies have suggested that tea consumption could lower the risk of dyslipidaemia. However, epidemiological evidence is limited, especially in southern China, where oolong tea is the most widely consumed beverage. We conducted a population-based case-control study to evaluate the association between consumption of tea, especially oolong tea, and risk of dyslipidaemia in Shantou, southern China, from 2010 to 2011. Information on tea consumption, lifestyle characteristics and food consumption frequency of 1651 patients with newly diagnosed dyslipidaemia and 1390 controls was obtained using a semi-quantitative questionnaire. Anthropometric variables and serum biochemical indices were determined. Drinking more than 600 ml (2 paos) of green, oolong or black tea daily was found to be associated with the lowest odds of dyslipidaemia risk (P< 0.001) when compared with non-consumption, but only oolong tea consumption was found to be associated with low HDL-cholesterol levels. A dose-response relationship between duration of tea consumption and risk of dyslipidaemia (OR 0.10, 95% CI 0.06, 0.16), as well as that between amount of dried tea leaves brewed and risk of dyslipidaemia (OR 0.34, 95% CI 0.24, 0.48), was found. Moreover, consumption of oolong tea for the longest duration was found to be associated with 3.22, 11.99 and 6.69% lower blood total cholesterol, TAG and LDL-cholesterol levels, respectively. In conclusion, the present study indicates that long-term oolong tea consumption may be associated with a lower risk of dyslipidaemia in the population of Shantou in southern China.
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Deqing
D
Yi
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Xuerui
X
Tan
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Zhiguo
Z
Zhao
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Yingmu
Y
Cai
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Yiming
Y
Li
Health Care Center, The Chaonan Minsheng Hospital, Shantou, Guangdong 515144, People's Republic of China.
Xiuying
X
Lin
Health Care Center, The Chaonan Minsheng Hospital, Shantou, Guangdong 515144, People's Republic of China.
Sailan
S
Lu
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Yongsong
Y
Chen
The Work Group of Chronic Disease Surveillance, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, People's Republic of China.
Qingying
Q
Zhang
D000328:Adult; D028241:Camellia sinensis; D016022:Case-Control Studies; D002681:China; D050171:Dyslipidemias / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D028321:Plant Preparations / Q000627:therapeutic use*; D013662:Tea
D028321:Plant Preparations; D013662:Tea